Qternmet XR FDA Approval History
Last updated by Judith Stewart, BPharm on Feb 4, 2021.
FDA Approved: Yes (Discontinued) (First approved May 2, 2019)
Brand name: Qternmet XR
Generic name: dapagliflozin, metformin hydrochloride and saxagliptin
Dosage form: Extended-Release Tablets
Company: AstraZeneca
Treatment for: Diabetes, Type 2
Qternmet XR (dapagliflozin, metformin hydrochloride and saxagliptin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, biguanide and dipeptidyl peptidase-4 (DPP-4) inhibitor combination indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Development timeline for Qternmet XR
| Date | Article |
|---|---|
| May 3, 2019 | Approval FDA Approves Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) for Type 2 Diabetes |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
